BRAF V600E-mutated anaplastic thyroid carcinoma (ATC) and treatment with BRAF-inhibitors: Real-world data from a single-institution, still far from the cure.

Published on May 25, 2020in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2020.38.15_SUPPL.E18577
Francesca Platini4
Estimated H-index: 4
,
Elisa Ortolan1
Estimated H-index: 1
+ 16 AuthorsLaura D. Locati30
Estimated H-index: 30
Source
Abstract
📖 Papers frequently viewed together
5 Citations
10 Citations
2013
References0
Newest
Cited By1
Newest
#1Kevin C. Miller (Harvard University)
#1Kevin C. Miller (Harvard University)H-Index: 4
Last. Ashish V. Chintakuntlawar (Mayo Clinic)H-Index: 11
view all 2 authors...
OPINION STATEMENT With a growing understanding of the biologic drivers of different thyroid cancers, there is an ongoing revolution in the treatment of aggressive and advanced disease variants. This includes matching patients with specific point mutations or gene fusions to targeted therapies (e.g., selective RET inhibitors), delineating patients who are likely to respond to immune checkpoint inhibition (i.e., PD-L1-positive tumors) and even priming responses to traditional therapies such as rad...
Source